



Bal Pharma Limited

22.9.2018

The Manager-Listing
BSE Limited
Mumbai.

To
The Manager-Listing
National Stock Exchange of India Ltd
Mumbai.

Dear Sir,

Sub: Proceedings of 31th Annual General Meeting ('AGM') held on 22.9.2018.
Ref : Scrip code 524824 for BSE and BALPH for NSE.

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting to the exchange the business transacted at the 31th Annual General Meeting of the Company held on 22.09.2018, at Bharatiya Vidya Bhavan, Race Course Road, Bangalore.


The Meeting commenced at 11.00 AM and concluded at 12.30 PM.

Ordinary Business:

1. Adopted the audited financial statements of the Company for the financial year ended 31.3.2018, together with Board's report and Independent Auditors Report.
2. Declared a dividend of Re.1/- per equity share of Rs.10/- each (i.e 10%), for the financial year ended 31.3.2018.
3. Ratified the appointment of NSVM & Associates, Chartered accountants as Statutory Auditors of the Company.

Special Business:

4. Approved to increase in investments limits of NRI's and FPI's in the share capital of the Company to 24% and 50% respectively.
5. Approved reappointment of Dr.Subba Rao Prasanna as Whole time Director of the Company for a tenure of 2 (two) years.
6. Ratified the remuneration payable to the Cost Auditors of the Company.



CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India
Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58
Email : info@balpharma.com Website : www.balpharma.com
CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph: 41570813 / 19 Fax: 41570820

Page-2

Kindly note that voting results will be announced after receipt of Scrutinizer's Report and the same will be submitted to the exchanges as per Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please take this intimation on record.

Thanking you

For Bal Pharma Limited


Shailesh Siroya
Managing Director

